New Eosinophilic esophagitis treatments are currently being studied. As of today, there are no eosinophilic esophagitis treatments that are FDA approved. On the horizon is Eohilia Budesonide Oral Suspension for Eosinophilic Esophagitis. Plus there are many other ways that EoE can be treated, but there are no official medications yet. Here we will discuss new eosinophilic esophagitis treatments under investigation.
Eosinophilic Esophagitis (EoE) Treatment
Eosinophilic Esophagitis (EoE) seems like the perfect fit for biologic medications, especially the ones that target IL-5. However, previous trials have not been very promising.
Xolair– Xolair was studied for EoE, unfortunately its data was not very impressive. It did not exhibit any reduction in eosinophil counts on repeat biopsy and only lead to mild improvement in symptom and quality of life scores.
Dupilumab-Dupixent was evaluated in phase 2 trials for EoE. It lead to a reduction in eosinophil levels and improvement in symptom and quality of life scores. It was dosed as 300mg weekly. Phase 3 data look promising.
Lirentelimab-Lirentelimab is a siglec-8 inhibitor being evaluated for EoE. Siglec-8 is expressed on mast cells, eosinophils, and basophils, and when targeted, it leads to destruction of eosninophils and prevent the release of stored and newly formed mediators of mast cells. This in turn leads to the decrease recruitment of local eosinophils. Studies showed a modest improvement in symptom and quality of life scores.
Nucala, Cinqair and Fasenra – All 3 IL-5 blockers are currently being studied as potential new treatments for eosinophilic esophagitis. All 3 lead to an expected reduction in tissue eosinophil levels. Improvement in symptoms and quality of life scores was seen.
Fasenra for Eosinophilic Esophagitis (EoE)
New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma
Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)
Dectrekumab (intravenous) and RPC4046 are 2 new anti-IL-13 agents currently being studied for use in EoE. Both lead to a reduction in tissue eosinophil counts.
Anti-IL-15 and anti-tumor necrosis factor alpha are 2 other classes of agents being explored for EoE.
It remains to be seen if any of these agents will pass clinical trials and be recommended for EoE in the future.